Tecartus Market Report 2026

Tecartus Market Overview

• The Tecartus market growth in the historic period has been driven by advancements in cellular immunotherapy research, increasing incidence of refractory blood cancers • Market expansion is supported by increasing investment in next-generation cell therapies, rising adoption of personalized oncology treatments • Growth Driver: Rising Prevalence Of Hematologic Cancers Driving Market Growth Due To Increasing Demand For CAR-T Cell Therapies • North America was the largest region in 2025.

What Is Covered Under Tecartus Market?

Tecartus is a CAR-T cell therapy used to treat certain blood cancers, such as relapsed or refractory mantle cell lymphoma (MCL) and B-cell acute lymphoblastic leukemia (ALL). It works by reprogramming a patient’s T-cells to target and destroy cancer cells, offering a personalized and targeted approach to treatment. The main types of indications for tecartus include mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and other hematologic cancers. Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma that affects the lymphatic system, and tecartus is used for patients with relapsed or refractory MCL to improve survival rates and reduce symptoms. The distribution channels include hospitals and specialty pharmacies for end users such as pediatric, adult, and geriatric

What Is The Tecartus Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investment in next-generation cell therapies, rising adoption of personalized oncology treatments, expansion of decentralized cell manufacturing models, growing focus on treatment durability, increasing clinical pipeline for car-t indications. Major trends in the forecast period include increasing adoption of car-t cell therapies, rising demand for personalized cancer treatments, expansion of advanced cell processing capabilities, growing focus on targeted hematologic oncology therapies, enhanced integration of gene engineering techniques.

Global Tecartus Market Segmentation

1) By Indication: Mantle Cell Lymphoma (MCL), Acute Lymphoblastic Leukemia (ALL), Other Hematologic Cancers 2) By Distribution Channel: Hospitals, Specialty Pharmacies 3) By End User: Pediatric, Adult, Geriatric

What Are The Drivers Of The Tecartus Market?

The rising prevalence of hematologic cancers is anticipated to drive the tecartus market going forward. Hematologic cancers refer to malignancies originating in the blood-forming tissues, such as bone marrow and lymphatic systems, and are characterized by abnormal cell growth and impaired blood cell function. The prevalence of hematologic cancers is increasing due to factors such as limited treatment options, especially in relapsed or refractory cases, and the growing incidence of these malignancies globally. Tecartus is essential for addressing hematologic cancers by offering an innovative treatment to improve patient outcomes. For instance, in January 2024, according to a report published by the American Cancer Society, a US-based nonprofit cancer advocacy organization, the estimates for acute lymphoblastic leukemia (ALL) (a type of hematologic cancer) in the United States for 2024 include approximately 6,550 new cases (3,590 in males and 2,960 in females) compared to 6540 in 2023. Therefore, the growing prevalence of hematologic cancers will drive the tecartus industry. The growing healthcare expenditure is expected to propel the growth of the tecartus market going forward. Healthcare expenditure is the total financial resources spent on healthcare services by governments, businesses, and individuals, including medical treatments, hospital care, medications, and public health initiatives. The rise in healthcare expenditure is due to advancements in medical technology, increasing healthcare needs, and an increasing emphasis on quality patient care, leading to higher investments globally. The increase in healthcare expenditure facilitates the establishment of advanced treatment centers capable of delivering CAR-T therapies, including the complex manufacturing and administration process required for tecartus. For instance, in July 2025, according to Healthcare Asia Magazine, a Japan-based health care industry publication, public health spending in Japan is forecast to grow at a average yearly rate of 5.0% i.e., estimated value of approximately $416 billion (JPY 60.17 trillion) in 2024 to reaching approximately $531 billion (JPY 76.78 trillion) by 2029. Therefore, growing healthcare expenditure drives growth in the tecartus industry. Growing awareness of personalized medicine is expected to propel the growth of the tecartus market going forward. Personalized medicine refers to a medical approach that tailors treatment and healthcare strategies to the individual characteristics, genetics, and needs of each patient. The rise in personalized medicine is attributed to advancements in genomics, biotechnology, and data analytics, allowing treatments to be customized based on individual genetic profiles and other personal health data. Growing awareness of personalized medicine supports the tecartus by increasing demand for autologous and targeted cell and gene therapies that improve efficacy, minimize side effects, and address specific patient needs. For instance, in February 2024, according to Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the growing awareness of personalized medicine is driving the growth of the tecartus industry.

Key Players In The Global Tecartus Market

Major companies operating in the tecartus market are Gilead Sciences Inc.

Regional Insights

North America was the largest region in the tecartus market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Tecartus Market?

The tecartus market consists of sales of autologous cell therapy (personalized treatment), infusion solution, cryopreserved formulation, and viral vectors for cell modification. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tecartus Market Report 2026?

The tecartus market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tecartus industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.